92 results
8-K
EX-99.1
RGLS
Regulus Therapeutics Inc
21 Mar 24
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
4:18pm
with no safety findings of concern. Greater biological activity of RGLS8429 was observed at 2 mg/kg based on urinary polycystin levels compared to 1mg/kg … will further explore at higher doses in cohorts 3 and 4.
The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety
8-K
EX-99.2
RGLS
Regulus Therapeutics Inc
14 Mar 24
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
4:57pm
study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult … the sample size to up to 30 patients. In addition to PC1 and PC2 and safety, imaging biomarkers will also be evaluated.
In the second cohort, 14 patients
8-K
EX-99.1
RGLS
Regulus Therapeutics Inc
9 Nov 23
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
4:15pm
is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS8429 in adult patients … observed, although not statistically significant.
In October 2023, the Company announced that, after a review of all available safety data in cohort two
8-K
EX-99.1
q8to6y
8 Aug 23
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
4:15pm
8-K
EX-99.1
qvqmunrqni8y43uq
11 May 23
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
4:16pm
8-K
EX-99.1
5jn251tq1o7
10 Nov 22
Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates
4:15pm
8-K
EX-99.1
0p4l4jmsybyk16x 7ol
11 Aug 22
Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
4:33pm
8-K
EX-99.1
qby4ukmrlno4 iply5c
12 May 22
Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
4:31pm
8-K
EX-99.1
j92u9nuygg txlltk0o
18 Oct 21
Other Events
6:06am
8-K
EX-99.1
yjr6r0uxmhybkrlpk8i
10 Aug 21
Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates
4:16pm